Lipocine (LPCN) Misses Q3 EPS by 67c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LPCN Hot Sheet
Join SI Premium – FREE
Lipocine (NASDAQ: LPCN) reported Q3 EPS of ($1.27), $0.67 worse than the analyst estimate of ($0.60).
For earnings history and earnings-related data on Lipocine (LPCN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Datadog stock tumbles 19% despite earnings beat
- Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
